Description
A Noninvasive Tool to Assess Liver Scarring
The FIB-4 test is a simple, noninvasive blood test used to estimate the amount of liver fibrosis (scarring) in individuals with chronic liver disease. It is particularly useful in patients with fatty liver disease, hepatitis C, or a history of alcohol use, and helps identify those who may be at risk for serious liver damage—such as cirrhosis.
How the Test Works:
The FIB-4 score is calculated using four key pieces of information:
- Age
- AST (Aspartate Aminotransferase)
- ALT (Alanine Aminotransferase)
- Platelet count
These values are combined into a formula to generate a FIB-4 score, which helps estimate the likelihood of significant fibrosis.
Understanding the Results:
A low score (below 1.30) suggests that there is a low likelihood of advanced liver fibrosis.
A score in the intermediate range (between 1.30 and 2.67) means the result is inconclusive—further testing or monitoring may be needed to assess liver health more accurately.
A high score (above 2.67) indicates a higher likelihood of advanced fibrosis or cirrhosis and may prompt your provider to recommend further evaluation, imaging, or referral to a liver specialist.
Why This Test Matters:
- Screens for liver scarring without the need for a biopsy
- Helps identify patients at risk for progression to liver failure
- Assists in determining next steps in treatment or monitoring
- Supports early intervention and better outcomes
Fasting not required.
